{"id":"W3138063460","doi":"10.1007/s00277-021-04465-4","title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"Incyte; Daiichi Sankyo Europe; Agios Pharmaceuticals; Jazz Pharmaceuticals; Celgene; Astellas Pharma; Ariad Pharmaceuticals; Alexion Pharmaceuticals; Servier; Pfizer; Amgen","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Hazard ratio; Leukemia; Oncology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001416412,0.0002579184,0.004132683,0.0007713266,0.00003201694,0.00000443198,0.0001922757,0.0003732019,0.0002583208],"category_scores_gemma":[0.001208205,0.0002026171,0.0005513211,0.00107548,0.0008433931,0.00009059849,0.0002481711,0.0005496943,8.937612e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006940418,"about_ca_system_score_gemma":0.001773887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001058862,"about_ca_topic_score_gemma":0.000159245,"domain_scores_codex":[0.9962256,0.0004740811,0.001880282,0.0005109046,0.0004396182,0.0004695154],"domain_scores_gemma":[0.9964053,0.00129538,0.000721657,0.0006238525,0.0007191982,0.0002345993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8614606,0.002670655,0.1214235,0.000505472,0.008111434,0.0008007378,0.0003805005,0.00001851118,0.000914547,0.0001950736,0.0001040947,0.003414874],"study_design_scores_gemma":[0.9161814,0.004416812,0.05955145,0.0002747776,0.002890968,0.0001236403,0.00004717706,0.0007855959,0.01547281,0.00007726963,0.000006267422,0.0001717702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996853,0.0009304546,0.0001004961,0.0007392207,0.00005478636,0.00105827,0.000126225,0.00001019888,0.0001273273],"genre_scores_gemma":[0.9972484,0.001151208,0.0007334408,0.0003530863,0.00002995196,0.0000443829,0.0003311866,0.00002614019,0.0000822708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06187207,"threshold_uncertainty_score":0.8262487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03271105453675983,"score_gpt":0.3778921484179776,"score_spread":0.3451810938812178,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}